Limits...
Association of the CYP24A1-rs2296241 polymorphism of the vitamin D catabolism enzyme with hormone-related cancer risk: a meta-analysis.

Wang P, Zhang H, Zhang Z, Qin L, Li B - Onco Targets Ther (2015)

Bottom Line: Subgroup analyses indicated that CYP24A1-rs2296241 variation reduced the prostate cancer risk in the additive (OR 0.91, 95% confidence interval 0.85-0.97) and recessive (OR 0.80, 95% confidence interval 0.67-0.95) models, with no evidence of heterogeneity.This meta-analysis indicated that CYP24A1-rs2296241 polymorphism reduced the androgen-related prostate cancer risk in additive and recessive models.More genetic loci are needed to confirm the effect of CYP24A1 variation on the risk of prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: Medical College of Soochow University, Suzhou, People's Republic of China.

ABSTRACT

Background: The evidence for vitamin D reducing cancer risk is inconsistent, and it is not clear whether this reduction is related to variation in cytochrome P450 (CYP)24A1, the only enzyme known to degrade active vitamin D. We focused on evaluating the association of CYP24A1-rs2296241 polymorphism with hormone-related cancer risk by conducting a meta-analysis.

Methods: A systematic literature search was conducted in April 2014 (updated in December 2014) to identify eligible studies. A random-effects model was used to pool the odds ratio (OR).

Results: Eleven studies including 5,145 cases and 5,136 controls were considered for the allelic model, and eight studies of 3,959 cases and 3,560 controls were utilized for the additive, recessive, and dominant models. There was no significant association between CYP24A1-rs2296241 and hormone-related cancer risk in any of the models, yet substantial heterogeneity was observed. Subgroup analyses indicated that CYP24A1-rs2296241 variation reduced the prostate cancer risk in the additive (OR 0.91, 95% confidence interval 0.85-0.97) and recessive (OR 0.80, 95% confidence interval 0.67-0.95) models, with no evidence of heterogeneity.

Conclusion: This meta-analysis indicated that CYP24A1-rs2296241 polymorphism reduced the androgen-related prostate cancer risk in additive and recessive models. More genetic loci are needed to confirm the effect of CYP24A1 variation on the risk of prostate cancer.

No MeSH data available.


Related in: MedlinePlus

Flowchart of study selection.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4447172&req=5

f1-ott-8-1175: Flowchart of study selection.

Mentions: We identified 97 potentially relevant articles in our initial search. Of these, 44 papers on laboratory studies were excluded after the first screening based on the abstract or title, leaving 53 articles for full-text review. We excluded 22 articles for not being case-control studies. Among the remaining 31 articles, five were excluded for only the survey of cancer tissues, three for the observation of tumor recurrence and death, ten for lacking gene locus data, four for not having pooled data, and two for not including hormone-related cancers. Finally, seven publications representing eleven studies were included in the meta-analysis. A flow chart showing the study selection is presented in Figure 1.


Association of the CYP24A1-rs2296241 polymorphism of the vitamin D catabolism enzyme with hormone-related cancer risk: a meta-analysis.

Wang P, Zhang H, Zhang Z, Qin L, Li B - Onco Targets Ther (2015)

Flowchart of study selection.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4447172&req=5

f1-ott-8-1175: Flowchart of study selection.
Mentions: We identified 97 potentially relevant articles in our initial search. Of these, 44 papers on laboratory studies were excluded after the first screening based on the abstract or title, leaving 53 articles for full-text review. We excluded 22 articles for not being case-control studies. Among the remaining 31 articles, five were excluded for only the survey of cancer tissues, three for the observation of tumor recurrence and death, ten for lacking gene locus data, four for not having pooled data, and two for not including hormone-related cancers. Finally, seven publications representing eleven studies were included in the meta-analysis. A flow chart showing the study selection is presented in Figure 1.

Bottom Line: Subgroup analyses indicated that CYP24A1-rs2296241 variation reduced the prostate cancer risk in the additive (OR 0.91, 95% confidence interval 0.85-0.97) and recessive (OR 0.80, 95% confidence interval 0.67-0.95) models, with no evidence of heterogeneity.This meta-analysis indicated that CYP24A1-rs2296241 polymorphism reduced the androgen-related prostate cancer risk in additive and recessive models.More genetic loci are needed to confirm the effect of CYP24A1 variation on the risk of prostate cancer.

View Article: PubMed Central - PubMed

Affiliation: Medical College of Soochow University, Suzhou, People's Republic of China.

ABSTRACT

Background: The evidence for vitamin D reducing cancer risk is inconsistent, and it is not clear whether this reduction is related to variation in cytochrome P450 (CYP)24A1, the only enzyme known to degrade active vitamin D. We focused on evaluating the association of CYP24A1-rs2296241 polymorphism with hormone-related cancer risk by conducting a meta-analysis.

Methods: A systematic literature search was conducted in April 2014 (updated in December 2014) to identify eligible studies. A random-effects model was used to pool the odds ratio (OR).

Results: Eleven studies including 5,145 cases and 5,136 controls were considered for the allelic model, and eight studies of 3,959 cases and 3,560 controls were utilized for the additive, recessive, and dominant models. There was no significant association between CYP24A1-rs2296241 and hormone-related cancer risk in any of the models, yet substantial heterogeneity was observed. Subgroup analyses indicated that CYP24A1-rs2296241 variation reduced the prostate cancer risk in the additive (OR 0.91, 95% confidence interval 0.85-0.97) and recessive (OR 0.80, 95% confidence interval 0.67-0.95) models, with no evidence of heterogeneity.

Conclusion: This meta-analysis indicated that CYP24A1-rs2296241 polymorphism reduced the androgen-related prostate cancer risk in additive and recessive models. More genetic loci are needed to confirm the effect of CYP24A1 variation on the risk of prostate cancer.

No MeSH data available.


Related in: MedlinePlus